Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Genentech Ends PARP Inhibitor Collaboration With Inotek

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Inotek focuses on two clinical candidates and consolidating operations.

You may also be interested in...



Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Start-up BiPar Seeks Fast Track In PARP Inhibition

Firm’s lead DNA repair candidate wins spot in Windhover Information’s Top 10 unpartnered oncology projects.

Genentech Gains PARP Inhibitor Through Inotek Deal

The lead product, INO-1001, is in Phase Ib for malignant melanoma.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

See All
UsernamePublicRestriction

Register

PS067718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By